Sirion Therapeutics Announces FDA Approval Of Durezol(TM) For Treatment Of Postoperative Ocular Inflammation And Pain

Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved its new drug application for Durezol(TM) (difluprednate ophthalmic emulsion) 0.05%, a topical steroid for the treatment of postoperative ocular inflammation and pain. The approval came after a six month priority review.

More: continued here

Filed under: Eye Health on June 30th, 2008